Citius Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTXR research report →
About the company
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
- CEO
- Leonard L. Mazur
- IPO
- 2014
- Employees
- 23
- HQ
- Cranford, NJ, US
Price Chart
- Market Cap
- $6.42M
- P/E
- -0.22
- P/S
- 1.14
- P/B
- 0.21
- EV/EBITDA
- -0.05
- Div Yield
- 0.00%
- Gross Margin
- 37.36%
- Op Margin
- -1041.44%
- Net Margin
- -823.34%
- ROE
- -67.42%
- ROIC
- -75.21%
- Revenue
- $0 · 0.00%
- Net Income
- $-37,433,911 · 4.36%
- EPS
- $-3.38 · 43.38%
- Op Income
- $-38,525,608
- FCF YoY
- 5.85%
- 52W High
- $2.24
- 52W Low
- $0.48
- 50D MA
- $0.63
- 200D MA
- $0.93
- Beta
- 0.98
- Avg Volume
- 630.63K
Get TickerSpark's AI analysis on CTXR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 8, 25 | Mazur Leonard L | other | 125,490 |
| Aug 8, 25 | Mazur Leonard L | other | 89,388 |
| Aug 8, 25 | Mazur Leonard L | sell | 125,490 |
| Aug 8, 25 | Mazur Leonard L | sell | 89,388 |
| Aug 8, 25 | HOLUBIAK MYRON Z | other | 31,373 |
| Aug 8, 25 | HOLUBIAK MYRON Z | other | 22,344 |
| Aug 8, 25 | HOLUBIAK MYRON Z | sell | 22,344 |
| Aug 8, 25 | HOLUBIAK MYRON Z | sell | 31,373 |
| Nov 7, 24 | Webb Carol | other | 125,000 |
| Nov 7, 24 | Smith Robert Joseph | other | 125,000 |
Our CTXR coverage
Recent articles, reports, and earnings notes.
No research on CTXR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTXR report →Similar companies
Peers in the same neighborhood.